Designing an Osmium(II) Complex to Inhibit the Growth and Recurrence of Tumors by Integrating Photodynamic Therapy, Chemotherapy, and Immunotherapy.
To effectively inhibit the growth and recurrence of tumors, we proposed to design a new osmium (Os) complex integrating photodynamic therapy (PDT), chemotherapy, and immunotherapy.
APA
Zhu M, Jiang M, et al. (2026). Designing an Osmium(II) Complex to Inhibit the Growth and Recurrence of Tumors by Integrating Photodynamic Therapy, Chemotherapy, and Immunotherapy.. Journal of medicinal chemistry, 69(8), 9334-9347. https://doi.org/10.1021/acs.jmedchem.6c00038
MLA
Zhu M, et al.. "Designing an Osmium(II) Complex to Inhibit the Growth and Recurrence of Tumors by Integrating Photodynamic Therapy, Chemotherapy, and Immunotherapy.." Journal of medicinal chemistry, vol. 69, no. 8, 2026, pp. 9334-9347.
PMID
41964570
Abstract
To effectively inhibit the growth and recurrence of tumors, we proposed to design a new osmium (Os) complex integrating photodynamic therapy (PDT), chemotherapy, and immunotherapy. To this end, we optimized a series of Os(II) complexes derived from differently modified thiosemicarbazone ligands to obtain an Os(II) 2-quinoxalinecarbaldehyde thiosemicarbazone complex (Os3) with remarkable cytotoxicity and phototoxicity to cancer cells. The establishment of an MC38 colon cancer xenograft model demonstrated that Os3 not only significantly inhibited the growth and recurrence of tumors but also exhibited few side effects. We confirmed that the antitumor ability of Os3 was attributed to the generation of phototoxicity, action on DNA, mitochondrial damage, induction of BRD4-mediated apoptosis, induction of ferroptosis, and activation of ferroptosis-mediated immune response.
MeSH Terms
Humans; Photochemotherapy; Animals; Immunotherapy; Osmium; Antineoplastic Agents; Coordination Complexes; Mice; Cell Line, Tumor; Apoptosis; Drug Design; Cell Proliferation; Photosensitizing Agents; Xenograft Model Antitumor Assays; Mice, Inbred BALB C
같은 제1저자의 인용 많은 논문 (5)
- Effects of botulinum toxin type A in patients with painful temporomandibular joint disorders: a systematic review and meta-analysis.
- A controllable self-amplifying oxidative stress strategy for boosting noninvasive sonodynamic therapy and synergistic immunotherapy.
- The circTIMP2/miR-106a/TIMP2 tumor-suppressive axis versus tumor-derived exosomal counteraction in gastric cancer.
- Regorafenib enhances anti-PDCD1/PD-1 therapeutic efficacy in colorectal cancer by promoting SQSTM1/p62-mediated CD274/PD-L1 degradation.
- CEP72 promotes malignant progression and shapes the tumor immune microenvironment in hepatocellular carcinoma: integrated multi-cohort bioinformatics and in vitro validation.